Clare WareingFounder

United Kingdom - Greater Edinburgh Area

Oncology drug development specialist for over 25 years.

Founder of Cumulus Oncology, a novel business model in Europe with proven investor value creation in the US. Cumulus Oncology was formed based on a career observing and implementing successful oncology drug development programmes in the biopharmaceutical sector. The founding team have similarly successful careers in the life science sector with some impressive biotech exits via company acquisitions.

Cumulus Oncology is actively creating new oncology biotech spin-out companies around novel assets, for which it provides executive support and governance. A previous exit from another successful oncology company, Nexus Oncology, a niche oncology CRO, has provided the financial resources, access to oncology assets and a global oncology drug development network to enable the ambitions of the company to be fulfilled.

Historical early phase oncology clinical development roles (Syntex,acquired by Roche, Astra acquired by Zeneca to create AZ), biotechs (ILEX Oncology) and CROs (IQVIA and Nexus Oncology). Career focus has been supporting companies developing innovative therapeutic approaches in oncology. Involved in the clinical development of 6 programmes that have lead to successful drug approvals in oncology.

Cumulus Oncology is interested in hearing from any organisations that have innovative oncology assets that would benefit from the business acumen and development expertise of the Cumulus Oncology team.